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INTERLEUKIN-8 AND 
MONOCYTE CHEMOTACTIC 
ACTIVATING FACTOR 
RESPONSES TO 
CARDIOPULMONARY 
BYPASS 
Cardiac operations with cardiopulmonary bypass cause a systemic inflam- 
matory response. Neutrophils and monocytes-macrophages play an impor- 
tant role in triggering the initiation of the inflammatory response. Recently, 
some kinds of cytokines that are powerful leukocyte chemotactic factors 
have been characterized concerning an inflammatory response: interleu- 
kin-8 has a potent chemoattractant activity for neutrophils, and monocyte 
chemoattractant factor has monocyte-macrophage chemotactic activity. To 
investigate the possible roles of the cytokines in the inflammatory response 
in cardiopulmonary bypass, 12 adult patients undergoing cardiopulmonary 
bypass were studied for measurement of interleukin-8 and monocyte 
chemoattractant factor. Systemic blood was collected before cardiopulmo- 
nary bypass, at the end of cardiopulmonary bypass, and at 3, 12, 24, and 48 
hours after cardiopulmonary bypass from the patients' radial arteries. 
Significant increases in levels of interleukin-8 and monocyte chemoattrac- 
tant factor were detected with a peak level at 3 hours after bypass compared 
with levels before cardiopulmonary bypass (p < 0.05). This study demon- 
strated that interleukin-8 and monocyte chemoattractant factor are re- 
leased into the circulation after adult hypothermic ardiopulmonary bypass 
and reach a maximum level 3 hours after bypass. (J THORAC CARDIOVASC 
SURG 1995;110:99-102) 
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C ardiac operations with cardiopulmonary bypass (CPB) cause a systemic inflammatory re- 
sponse. 1-3 A degree of tissue injury and associated 
organ dysfunction, particularly in the heart and 
lungs, is usual after CPB. 3-5 This is thought o be a 
result principally of a combination of inflammation 
induced by (1) exposure of blood to an artificial 
surface 1, 3, 4, 6 and (2) reperfusion injury on discon- 
tinuation of bypass)' 7, 8 Recently, a group of cyto- 
kines with chemotactic and activating effects on 
leuk0cytes (so.called chemokines) has been de- 
scribed: interleukin-8 (IL-8) has potent chemoat- 
tractant activity for neutrophils, 9' 10 and monocyte 
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chemoattractant factor (MCAF) has monocyte-mac- 
rophage chemotactic activity. H' 12 To Our knowl- 
edge, however, IL-8 has been reported previously in 
human beings during CPB by only a few research, 
ers,13, 14 and MCAF has not been reported during 
CPB. 
On this basis, we performed a prospective self- 
controlled study to examine the circulating concen- 
trations of IL-8 and MCAF before, during, and after 
operations with the use of CPB. 
Patients and methods 
Twelve adult patients (4 men, 8 women) undergoing 
elective cardiac and aortic operation with CPB at our 
institution comprised the study population. Patients' ages 
ranged from 48 to 75 years (mean 62.9 _+ 9.9 years). All 
CPB procedures were done at moderate hypothermia 
(28 ~ C) with cold blood cardioplegia. The duration of 
cardioplegic arrest varied from 29 to 168 minutes (mean 
95.3 + 12.0 minutes) and CPB times ranged from 89 to 
234 minutes (mean 155.8 -+ 12.0 minutes). The types of 
operations done were aortic valve replacement in five 
patients, mitral valve replacement in three patients, as- 
cending aorta replacement in three patients, and ventric- 
ular septal perforation repair in one patient. All received 
a similar balanced anesthetic, including sufentanyl citrate, 
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Table I. Cytokine levels in serum (in picograms per milliliter) 
pre-CPB end-CPB 3 hr 12 hr 24 hr 48 hr 
IL-8 2.3 + 0.9 8.0_+ 2.0 187.3 +_ 100.9" 23.6_+ 4.4 11.9 + 2.9 2.8 +_ 1.0 
MCAF 97.1 _+ 20.8 193.0 +- 32.2 2519.2 _+ 940.0* 470.8 + 144.4 153.8 +_ 24.2 128.8 _+ 25.1 
Values are mean plus or minus the standard error of the mean, Each mean represents values from 12 patients. 
End-CPB, At the end of CPB; hi; hours after CPB. 
*p < 0,05 versus pre-CPB. 
inhaled isoflurane, and a neuromuscular blocking agent. 
Steroids were not used in any of the patients: 
Arterial blood samples were drawn from the patients' 
radial arterial lines as follows: before CPB, at the end of 
CPB, and 3, 12, 24, and 48 hours after CPB. 
Serum was separated immediately b centrifugation a d 
stored at -20~ Until use. Serum concentration was 
measured by enzyme-linked immunosorbent assay kits 
(TORAY Inc., Shiga, Japan), which were previously de- 
velopedJS. 16 The assay was done in duplicate for each 
sample. 
Cytokine levels at various occasions were compared 
with pre-CPB values by repeated-measures analysis of 
variance followed by Fisher's protected least significant 
difference with analysis of variance. Results are expressed 
as mean plus or minus the standard error of the mean, and 
p < 0.05 is considered to be significant. 
Results 
All patients had an uncomplicated recuperation 
and left the hospital uneventfully. 
Table I presents pooled data for all patients 
showing changes in plasma concentrations of IL-8 
and MCAF as a function of time. These data are 
represented graphically in Figs. 1 and 2. The influ- 
ence of CPB on cytokine levels is shown by a 
significant increased in levels of both IL-8 and 
MCAF 3 hours after CPB compared with pre-CPB 
levels (p < 0.05). After the peak value was reached, 
concentrations fell in postoperative specimensl Al- 
though these remained detectable 24 hours later, 
the concentrations returned to baseline levels after 
48 hours. 
Discussion 
Previous reports have indicated that infiltrating 
leukocytes play an important role in inflammatory 
response during surgical intervention, extracorpo- 
real circulation, reperfusion injury, and infection. 
Recently, IL-8 and MCAF were characterized as 
potent leukocyte chemotactic and activating factors. 
IL-8 is produced by a variety of cell types including 
endothelial cells, monocytes, and T-lymphocytes. 
IL=8 is believed to have a key role in the accumula- 
tion of neutrophils in inflamed tissue. 9' lO It upregu- 
lates complement receptor-117 and leukocyte adhe- 
sion molecule Mac-1 (CD11b/18) 18 and stimulates 
neutrophil adhesion to endothelial cells, as well as 
exerting potent chemoattractant ac ivity for neutro- 
phils,9. 10 basophils, and T-lymphocytesJ 9; 2o Al- 
though MCAF is produced by a variety of cells 
including endothelial cells, fibroblasts, and vascular 
smooth muscle cells, it activates and attracts mono- 
cytes. Also, IL-1 and tumor necrosis factor have 
been shown to induce IL-8 and MCAF gene expres- 
sion at the transcriptional level. TM 21 
Our results indicated that a significant increase in 
IL-8 was detected with a peak level at 3 hours aftei 
bypass. Previously, some researchers eported IL-8 
plays a role as a major mediator of the acute phase 
response to CPB. Finn and colleagues 13reported 
that levels of IL-8 rose at the time of rewarming, 
toward the end of bypass, and peaked 1 to 3 hours 
"thereafter in children. 13 Kalfin and colleagues 14
reported that a significant increase in IL-8 levels was 
detected in circulating leukocytes with a peak level 
at 24 hours after bypass, but they did not perform 
measurements within 24 hours after bypass. The3 
stated it is likely that IL-8 would have increased 
dramatically in the early post-CPB phase. 14 
To our knowledge, MCAF has not been reportec 
previously in the human patient during CPB. Om 
results show that MCAF was also released anc 
appeared in the systemic irculation in the earl? 
post-CPB phase and that it reached a peak level al 
3 hours after bypass imilar to the finding for IL-8 
Kappelmayer and colleagues 22reported that tissue 
factor expression and procoagulant activity are in. 
duced by monocytes during extracorporeal circula. 
tion, which leads to the suggestion that this ma? 
contribute to the increased risk of thromboembolic 
events during the period of prolonged extracorpo 
real circulation. These data suggest hat activatior 
of monocytes and macrophages during CPB ma~ 
also be important from the thrombogenic point o 
view. 
During CPB, it is suspected that inflammatoP 
responses are induced by not only exposure of blooc 
to artificial surfaces, but also by reperfusion injur. 
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Fig. 1. Changes in circulating concentrations of IL-8 as 
function of time in patients undergoing CPB. Points of 
collection are just before initiation of CPB (pre-CPB), at 
end of CPB (end CPB), 3 hours after completion of CPB, 
12 hours after CPB, 24 hours after CPB, and 48 hours 
after CPB. Error bars indicate standard error of mean. 
*p < 0.05 versus pre-CPB. 
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Fig. 2. Changes in circulating concentrations of MCAF 
as function of time in patients undergoing CPB. Points of 
collection are just before initiation of CPB (pre-CPB), at 
end of CPB (end CPB), 3 hours after completion of CPB, 
12 hours after CPB, 24 hours after CPB, and 48 hours 
after CPB. Error bars indicate standard error of mean. 
*p < 0.05 versus pre-CPB. 
9 on discontinuation of bypassJ' 3, 4, 6-8 In experimen- 
tal models of ischemia/reperfusion njury, it is con- 
sidered that newly recruited neutrophils are capable 
of mediating extensive tissue damage. 23-25 Although 
it is presently unclear what role IL-8 plays in attract- 
ing neutrophils to reperfused tissue sites in vivo, 
some researchers have discussed the relationshi p 
between IL-8 and reperfusion i jury. 26, 27 Clinically, 
Abe and colleagues 26reported that the serum IL-8 
concentration showed a transient rise during the 
early phase of acute myocardial infarction. 
In summary, our preliminary results show that 
IL-8 and MCAF were released and appeared in the 
systemic circulation in the early post-CPB phase. 
These results uggest that these cytokines play a role 
as major mediators of the acute phase response to 
CPB and would provide sensitive parameters of 
inflammatory responses during CPB. Furthermore, 
if IL-8 and MCAF responses to CPB are important, 
there are several potential therapeutic possibilities. 
The ability of monoclonal antibodies against IL-8 
and MCAF to inhibit postperfusion i jury and in- 
flammatory response may be, in part, secondary to a 
decrease in production of these chemokines, a sub- 
sequent reduction in the elimination of neutrophils, 
and a prevention of tissue damage after CPB. 
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